Translational PET imaging research
The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomogr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-01-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996113002507 |
| _version_ | 1818728774282248192 |
|---|---|
| author | Richard J. Hargreaves Eugenii A. Rabiner |
| author_facet | Richard J. Hargreaves Eugenii A. Rabiner |
| author_sort | Richard J. Hargreaves |
| collection | DOAJ |
| description | The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs. CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy. |
| first_indexed | 2024-12-17T22:35:20Z |
| format | Article |
| id | doaj.art-56e97bf2a1ad430aae73c1f8631836d0 |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-17T22:35:20Z |
| publishDate | 2014-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-56e97bf2a1ad430aae73c1f8631836d02022-12-21T21:30:06ZengElsevierNeurobiology of Disease1095-953X2014-01-01613238Translational PET imaging researchRichard J. Hargreaves0Eugenii A. Rabiner1Merck and Co, WP-42-212, 770, Sumneytown Pike, PO Box 4, West Point, PA19486, USA; Corresponding author.Imanova Limited Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK; Centre for Neuroscience Imaging, Institute of Psychiatry, King's College London UKThe goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs. CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy.http://www.sciencedirect.com/science/article/pii/S0969996113002507Positron emission tomography (PET) imagingDrug developmentTarget engagement imagingPsychiatry imaging |
| spellingShingle | Richard J. Hargreaves Eugenii A. Rabiner Translational PET imaging research Neurobiology of Disease Positron emission tomography (PET) imaging Drug development Target engagement imaging Psychiatry imaging |
| title | Translational PET imaging research |
| title_full | Translational PET imaging research |
| title_fullStr | Translational PET imaging research |
| title_full_unstemmed | Translational PET imaging research |
| title_short | Translational PET imaging research |
| title_sort | translational pet imaging research |
| topic | Positron emission tomography (PET) imaging Drug development Target engagement imaging Psychiatry imaging |
| url | http://www.sciencedirect.com/science/article/pii/S0969996113002507 |
| work_keys_str_mv | AT richardjhargreaves translationalpetimagingresearch AT eugeniiarabiner translationalpetimagingresearch |